Summary:
- The article discusses the development of a new oral drug candidate called REGEN-COV, which is a combination of two monoclonal antibodies (casirivimab and imdevimab) for the treatment of COVID-19.
- The drug has been granted Emergency Use Authorization (EUA) by the U.S. Food and Drug Administration (FDA) for the treatment of mild to moderate COVID-19 in adults and pediatric patients.
- The article highlights the potential benefits of REGEN-COV, including its ability to reduce the risk of hospitalization or death in high-risk COVID-19 patients, and its potential to be effective against emerging variants of the SARS-CoV-2 virus.